Comparing the current results to its competitors, An2 Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.22 %, recorded in the same quarter.
An2 Therapeutics Inc , slower than the average decrease reported by the company's competitors of -77.27 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -77.27 %
An2 Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape for epetraborole, if approved, will depend on its ability to compete with existing therapies and those in development. Key factors influencing competition include market opportunity size, pricing, coverage, reimbursement, business model implementation, strategic plans, intellectual property protection, and the identification of additional product candidates.
July 23, 2025
Chagas disease, caused by the parasite Trypanosoma cruzi , represents a significant public health challenge affecting approximately 6 to 7 million people worldwide. This neglected tropical disease can lead to severe chronic complications, including cardiomyopathy and gastrointestinal manifestations, severely impacting patients quality of life. Recent developments in medicinal chemistry are promising new avenues for effective treatments, particularly through novel small molecules. AN2 Therapeutics, Inc., in collaboration with the Drugs for Neglected Diseases initiative (DNDi), has taken significant strides in developing AN2-502998, an oral compound aimed explicitly at addressing the needs of chronic Chagas...
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Sources:
An2 Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on An2 Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
